Studies in progress : I want to apply to this clinical study

Are you or a loved one affected by Sjogren's Syndrome ? Join our innovative clinical study and help advance research against this debilitating disease.

Why Participate?

Sjögren's Syndrome is a rare autoimmune disease that affects millions of people worldwide. Symptoms can be debilitating, ranging from dry eyes and mouth to joint and muscle pain. Our clinical study is an opportunity to make a significant difference in the lives of our participants with this disease.

The Benefits of Participation

  • Access to cutting-edge treatments: You will have access to the latest advances in the field of research against Sjögren's Syndrome.
  • Free medical care: Participants in our clinical study receive free medical care, including consultations with our experts.
  • Contribute to research: Your participation will help advance the understanding and treatment of Sjögren Syndrome.
  • Financial compensation: Participants will receive financial compensation for their time and travel.

Participation Criterias

  • Be aged 18 and over
  • Have been diagnosed with Sjögren's Syndrome for less than 10 years

How to participate

  • Complete the contact form below to express your interest in participating in our clinical study.
  • Our research team will contact you to discuss your eligibility and answer your questions.
  • If you are eligible, you will be invited to participate in the clinical study.
  • Your Contribution Matters.

By participating in our clinical study, you become an essential link in the fight against Sjögren Syndrome. Together, we can improve the quality of life of patients and advance medical research. Fight Sjögren Syndrome by participating in our clinical study

For more information, contact us at 819 346-2887 (Sherbrooke) or at 1-844-739-3439 (toll free), or fill the online form. Succursale : Sherbrooke

I want to apply to this clinical study : https://www.diex.ca/nos-etudes/maladie-de-sjogren/

2024-07-11

Studies in progress : Sjögren' Syndrome

Sjögren's syndrome is an autoimmune disease, which occurs when the immune system is out of balance. In Sjögren's syndrome, the white blood cells of the immune system attack the glands responsible for lubrication and other tissues in the body. This explains the constant dryness of your eyes and your mouth. Researchers suspect that the immune response could be due to several factors, including viral infections, hormonal changes and stress. A genetic factor could also come into play, because sometimes related conditions are observed in members of the same family.

It may be possible for you to participate in this study if:

  • YOU ARE BETWEEN 18 AND 80 INCLUSIVELY
  • YOU HAD A DIAGNOSIS OF THE ILLNESS FOR 7 YEARS OR UNDER.

For more information, contact us at 819 346-2887 (Sherbrooke) or at 1-844-739-3439 (toll free), or fill the online form. Succursale : Sherbrooke

I want to apply to this clinical study : https://www.diex.ca/nos-etudes/syndrome-de-sjogren/

2024-07-12

Research project on dry eyes with Sjögren's syndrome at CHUM Montreal

If you suffer from dry eyes, have been diagnosed with Sjögren's disease, or are in the process of being diagnosed, and would like to participate in this research project, please contact us. A clinic is being offered on August 2, 2023 in Montreal for a non-invasive tear collection using a Schirmer strip (most of us have experienced such a collection during regular visits to the ophthalmologist).

Are you interested in taking part in this research project?

Please leave your contact details at the following e-mail address: sjogrenquebec@gmail.com. Pour For more information, please contact us at 514-934-3666. The contact details of those interested in participating in this research project will be sent to the researchers in charge. You will then be contacted directly by the research center to confirm the date and time of your appointment.

This is a great opportunity for us to advance research for better diagnosis.

2023-07-29

NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved

In NEPTUNUS-2, a phase III study, Novartis and Dr. Isabelle Fortin are testing the efficacy and safety of Ianalumab in patients with Sjögren Syndrome, a rare disease. This study, which is taking place in 195 sites in 30 countries and aims to recruit 489 patients across the globe, was authorized in Quebec in 8 weeks by the Centre intégré de santé et de services sociaux du Bas-Saint-Laurent– Dre Isabelle Fortin, rhumatologue, CISSS Bas-Saint-Laurent.

2022-12-08